Updated Edition 2021 CGMP Cell & Gene Therapy
Transcript of Updated Edition 2021 CGMP Cell & Gene Therapy
VigeneBiosciencesA Charles River Company
CGMP Cell &
AAV, Adenovirus, and LentivirusPD and Production Handbook
Updated Edition 2021
Gene Therapy
Vigene CGMP overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3
Vigene manufacturing technologies and platforms . . . . . . . . . .5
Facilities and Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
Production Cell Lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Purification Process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
Vigene manufacturing services . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
AAV manufacturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
Adenovirus manufacturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Lentivirus manufacturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
GMP-ready plasmid manufacturing . . . . . . . . . . . . . . . . . . . . . . 11
BSL-3 virus manufacturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Aseptic filling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Cell and virus banking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
AAV QC and plasmid DNA QC assays . . . . . . . . . . . . . . . . . . . . . 13
Process development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Table of Contents
www.vigenebio.com © 2021 Vigene Biosciences
3AAV, Adenovirus and Lentivirus Gene Therapy CGMP PD and Production Handbook
Vigene - the CGMP Viral Vector Experts
Vigene’s mission is to make gene therapy affordable .
We strive to achieve our vision by combining new manufacturing technologies and high yield production cell lines with a rigorous quality control system for CGMP .
Vigene Biosciences, Inc . (hereafter Vigene) is a leading gene and cell therapy contract development and manufacturing organization (CDMO) that strives to deliver the highest quality processes and products to our clients .
Vigene’s two divisions (basic research and CGMP production) work together seamlessly to offer “concept to commercial” capability to our clients .
On the basic research side, Vigene is developing, manufacturing, and distributing state-of-the-art AAV, lentivirus, retrovirus, and adenovirus based reagents including HHMI/Janelia Research Campus AAV Biosensors .
On the CGMP clinical production side, Vigene is combining proven production technologies with rigorous regulatory compliant CGMP production to meet the needs and expectations of clinical material clients . Vigene offers FDA and EMA compliant CGMP production for AAV, lentivirus, adenovirus, retrovirus, and plasmids . Headquartered in Rockville, MD, Vigene is a leader of both research grade and CGMP grade AAV, lentivirus, adenovirus, retrovirus, and plasmids, serving over 4,000 academic, biotech, and pharmaceutical labs .
Vigene is constantly striving to consistently provide high-quality clinical phase biologic products and services to meet the needs and expectations
Vigene Biosciences4 www.vigenebio.com
of our customers in gene delivery technologies . Our management and employees comply with CGMP regulations including 21 CFR 11, 210, 211, and 610 and the relevant EU CGMPs . By 2022, Vigene will be operating 15 state-of-the-art CGMP production suites with a total of 110,000 sq ft cleanroom space .
Our facilities meet all US and EU requirements for Phase I & II . The new facilities and systems will meet Phase III and commercial stage clinical material manufacturing requirements . We have been successfully audited by multiple biotech and pharma clients . All products are segregated and produced on a campaign basis and validated change-over and cleaning procedures are deployed between each project . Currently, more than 40 batches of clinical materials have been successfully produced and released .
Vigene features strong Process Development and CGMP teams with accomplished virologists and technologists . In addition, we have an experienced team of Quality Assurance (QA) and Quality Control (QC) professionals who work alongside the facility team, material team, PD team, and CGMP team to ensure end-to-end quality compliance .
Previous CGMP grade clinical materials:1 . Adeno-Associated Virus (Lot sizes of 1E+15 – 1E +16 viral
genome or VG)2 . Adenovirus (Lot sizes of 1E+12 – 1E +13 viral particles or VP)3 . Lentivirus (Lot size of 1E+10 – 1E +12 Infectious Units or IFU)4 . Other viruses (HIV, dengue virus, HPV etc)
5AAV, Adenovirus and Lentivirus Gene Therapy CGMP PD and Production Handbook
Vigene Manufacturing Technologies and Platforms
Facilities and Technologies
Fifteen carefully designed CGMP production suites allow parallel campaigns and maximal flexibility in customizable bioprocesses . We leverage proprietary production cell lines and experienced manufacturing teams, as well as partnerships with leading technology innovators to provide a variety of scalable bioprocesses and superior product quality based on our clients’ material needs, budget, and long-term development plans .
Facility Highlights:• 15 state-of-the-art CGMP production suites (110,000 sq ft); Independent HVAC systems for
all CGMP production suites • Compliant and unidirectional personnel, material and product flow• Successfully audited by EMA and FDA-compliant clients• 24-hour monitoring and notification service on facility and critical equipment• Vigene places a heavy reliance on disposable systems to reduce changeover and validation
costs
Suspension process Ultracentrifugation
Chromatographypurification
Adherent process
iCELLis 500 (m2)
Upstream platforms Downstream platforms
Stirred-Tank Reactor 200L-500L
Vigene Biosciences6 www.vigenebio.com
Production Cell LinesSuspension HEK293 and 293T Vigene has developed proprietary suspension
HEK293 and 293T cell lines that grow under animal component-free conditions . The cell lines are optimized for rapid and scalable production of all serotypes and chimeras of adeno-associated virus (AAV) and can also be developed for adenovirus, retrovirus, and lentivirus production . Vigene has also developed a proprietary suspension-culture-based helper-free process for AAV production using our production cell lines with typical yields of 1E+5 - 1E+6 GC/cell . The suspension
HEK193 and 293T cells are fully qualified and released for CGMP viral vector production .
Production Cell Lines We understand that some clients may choose to provide their own cell line for manufacturing .
If you have already developed a producer cell line that you wish to use for your project, we can use that line to establish master and working cell banks . Alternatively, we can develop your cell line into an efficient AAV producer cell line, adenovirus producer cell line, or lentivirus producer cell line . For example, we can adapt your preferred adherent cell line for suspension growth .
VigeneBiosciencesA Charles River Company
High yield proprietary production cell line
We can adapt your preferred adherent cell line for suspension growth.
7AAV, Adenovirus and Lentivirus Gene Therapy CGMP PD and Production Handbook
Cell Culture Process Scale-up of adherent cell culture The scale-up of adherent cell culture using HYPERstacks or roller bottles can be very labor intensive and inefficient . Vigene uses iCELLis 500 (Pall Life Sciences), the world’s first fully-integrated, single-use high-density adherent cell culture bioreactor to scale up adherent HEK293, 293T and HeLa culture processes . Central to the iCELLis bioreactor technology is the use of a compact fixed-bed, filled with custom macrocarriers . This matrix provides up to 500 m2 available area for cell growth, which is surface-equivalent of 3,000 Roller Bottles (1700 cm2) or 277 HYPERStacks (36 Layers) .
Scale-up of suspension cell cultureVigene uses 200L - 500L single-use stirred-tank bioreactors for high density culture of suspension cells (HEK293-S, 293T-S, HeLa-S and sf9 insect cells) . High titer viral vectors can be produced through either transfection or infection method in batch mode . Bioreactor systems can also be operated in fed-batch and perfusion modes to enhance the upstream process and increase volumetric yield .
Vigene Biosciences8 www.vigenebio.com
Purification ProcessUltracentrifugation Vigene has extensive experience in iodixanol gradient ultracentrifugation for virus isolation and
empty/full capsid separation . However, due to the limited scalability and evolving regulatory guidance, we only recommend this method for small amounts of materials for early stage studies or when chromatography-based purification methods are not available .
Chromatography-based purificationVigene has the capability of processing 200L - 500L batches with microfluidization, chemical in-tank lysis, depth filtration, tangential flow filtration and multi-column chromatography purification . Process optimization services can be provided to improve recovery rate and impurity removal . A comprehensive range of impurity assays has been established to monitor residual impurities including polyethylenimine, host cell protein, residual plasmid DNA, host cell genomic DNA, etc . Refer to AAV/Plasmid DNA QC assays for more information .
9AAV, Adenovirus and Lentivirus Gene Therapy CGMP PD and Production Handbook
Vigene Manufacturing Services
AAV Manufacturing Upstream production platforms
• Triple transfection of adherent cells (HEK293, 293T cells)• Triple transfection of suspension cells (HEK293, 293T cells)• Baculovirus based AAV production (Sf9 cells) • Helper virus based production of adherent cells (HEK293, 293T cells)• Helper virus based production of suspension cells (HEK293, 293T cells)
Vigene has developed scalable and proprietary upstream platforms consisting of high producing HEK293 cell lines (typically produce at 1E+5 - 1E+6 GC/cell) and optimized adherent/suspension culture transfection methods for rAAV production . We typically produce at >1E+14 GC/L with both adherent and suspension HEK293 platforms . In addition, CGMP Master Cell Banks have been created and fully tested for both adherent and suspension HEK293 cell lines, allowing streamlined manufacturing and cutting down campaign time .
Downstream purification platformsWe offer iodixanol gradient ultracentrifugation and large-scale chromatography purification services (IEX, AEX, affinity, SEC, etc .) based on our clients’ preferences, material needs, timelines and long-term development plans . With our experienced production, QA and QC teams, Vigene has the expertise and confidence in operating controlled processes to deliver products with optimal yield and purity to our clients .
Transient plasmidtransfection
Adherent HEK293/293T
Adherent HEK293/293TAdherent HeLa
Suspension HEK293/293T-s
Suspension HEK293/293T-sSuspension HeLa-s
Suspension sƒ
Helper virusco-infection
Baculovirus-insect cells
GMP-ReadyTM plasmidmanufacturing
Proprietaryhigh-yield
suspension cell lines
Exclusive license forBAC-to-AAVtechnology
Virus packaging method
Vigene Biosciences10 www.vigenebio.com
Adenovirus ManufacturingAdenovirus Production The CGMP production of clinical grade adenovirus vectors requires knowledge of the complex methods to generate, purify and characterize adenovirus vectors in a well established proven CGMP quality system . As a leader of adenovirus vector production, Vigene combines the leading adenovirus production technology with comprehensive CGMP procedural controls that have been developed to ensure clinical product quality, safety and consistency .
AdenovirusVigene has developed proprietary, highly efficient, and reproducible systems for high titer adenovirus production .
Production yields purified adenovirus for clinical trials in batch sizes of 1 x 1015 viral particles .
Process Specifications• Robust TFF concentration and ion exchange purification process, capable of handling culture
volumes in excess of 30 liters .• Final formulation based on client requirements
Lentivirus ManufacturingLentivirus Production The CGMP production of clinical grade lentivirus vectors for CAR-T and gene therapies requires knowledge of the complex methods to generate, purify and characterize lentivirus vectors in a well established proven CGMP quality system . As a leader of lentivirus vector production, Vigene combines the leading lentivirus production technology with comprehensive CGMP procedural controls that have been developed to ensure clinical product quality, safety and consistency for CAR-T and gene therapy clinical trials .
Vigene has developed a proprietary and highly efficient system for ultra high titer lentivirus pro-duction at clinical scale . The scalable system process for lentivirus production utilizes adherent 293T with titers of 109- 1010 IFU/ml and a total batch size up to 5x1012 IFU .
Process Specifcations• Optimized calcium phosphate transduction protocol• Closed system purification/concentration processing (TFF/ultracentrifugation)• In-house p24 ELISA, RT-PCR assays, and functional titration assays• Final product yields typically 1E+9 IFU/ml range
11AAV, Adenovirus and Lentivirus Gene Therapy CGMP PD and Production Handbook
GMP-ReadyTM and CGMP plasmid manufacturing Vigene manufactures GMP-Ready grade and CGMP grade plasmid DNA to support plasmid transfection-based viral packaging campaigns . With material segregation, full traceability, document control and a comprehensive range of plasmid DNA quality control assays, GMP-Ready plasmid DNA can be used as critical raw material for clinical manufacturing campaigns . Refer to AAV/plasmid DNA QC assays for more information .
• Plasmid productions are conducted in segregated and dedicated production suites . Each plasmid is segregated from other plasmids and plasmid-bearing materials using physical barriers to maintain isolated manufacturing conditions .
• Full room changeover occurs prior to initiation of new projects including cleaning of surfaces and non-disposable equipment .
• For GMP-Ready Plasmids, the final fill and finish can either be in the CGMP facility (Grade-A BSC in Grade B room) or in a Biosafety Cabinet (BSC) in a non-CGMP facility with a cleaning procedure between different plasmids .
• Dedicated CGMP suites for GMP plasmids production• Complete QC monitoring throughout production process and QA oversight for CGMP
plasmids production • Vialed in an ISO 5 environment for CGMP plasmids
Vigene Biosciences12 www.vigenebio.com
Aseptic Filling200-2000 Vials per day Small-scale aseptic filling of viral and non-viral products are available on site . Vialing capacity of 200 - 2000 vials per day is available with fill volumes ranging from 10 μl to 100 ml .
Key Benefits of Vigene’s Aseptic Filling Services• CGMP aseptic filling of viral and infectious materials• Documented to meet FDA requirements for Phase I/II and Phase III/ Commercial clinical
manufacture• Pricing is based on runs for a small, not large, facility
Please contact us to discuss your filling needs . If we are unable to assist you, we will guide you to others who might .
Cell & Virus BankingMCB & WCB; MVB & WVB The establishment of compliant, robust, and traceable cell and viral banks is critical for CGMP production . Banking of master and working cell banks (MCB, WCB) for mammalian cells is performed in a separate area designed for these activities . Viral banking services are completely
segregated from non-viral activities to ensure no cross-contamination of products .
Mammalian Cell Banks• Base master & working cell lines (eg, HEK-293, Vero)• Stable recombinant protein/antibody expressing lines (CHO, NS/0, BHK-21)• Human and non-human stem cells
Viral Banks• Viral Seed Stocks• Viral vectors for gene delivery (adenovirus, retrovirus, lentivirus, AAV, others)• Viral vectors for vaccines (live, attenuated, and whole-killed)• Banking/vialing of purified phage
Quality assays for release of all banks are performed by outside testing firms to ensure safety and stability of these products .
13AAV, Adenovirus and Lentivirus Gene Therapy CGMP PD and Production Handbook
AAV QC and Plasmid DNA QC Assays We offer a comprehensive range of assay development and in-process testing services to ensure the identity, quality and purity of your product and to reduce the overall costs and time it takes to get your product to the clinic .
Our current assay capabilities are:• Purity and Impurities Viral vector purity (SDS-PAGE, silver stain) Residual polyethylenimine (SDS-PAGE) Residual iodixanol (HPLC) Residual Host Cell Protein (ELISA) Residual Host Cell DNA (qPCR) Residual Plasmid DNA (qPCR) Residual benzonase (ELISA)
Residual PEI (HPLC)
• Strength Vector genome titer (qPCR, ddPCR) Total viral particle titer (ELISA)
• Microbiological Safety and Quality Bioburden (Direct inoculation) Endotoxin (LAL/Chromogenic method)
Vigene Biosciences14 www.vigenebio.com
Process Development Critical to ensuring successful and economical production is having a robust and optimized manufacturing process . The goals of process development (PD) include:
- Maximizing the capacity of a production platform- Establishing a scalable, reproducible and robust manufacturing process- Reducing manufacturing costs- Extending intellectual property protection or proprietary know-how through innovation- Satisfying the regulatory requirements necessary for FDA approval
The development and optimization of biologics manufacturing processes is a difficult and complex task . For small firms, acquiring PD capabilities is expensive and often off-focus . Contracting your PD needs to Vigene allows our clients to focus on discovery and scientific research while we take on the industrial development . Vigene’s PD team works hard to ensure that you have a process that meets FDA regulatory requirements, reduces your costs going forward and maintains high quality standards .
Vigene provides the following process development services: • Process optimization using scale-down models (iCELLis® Nano, T-flask, shake flask, 1L STR
bioreactors)• Cell line engineering and adaptation• Media/feed screening and optimization• Transfection/infection optimization • High cell density culture and transfection/infection• Harvest, lysis, and clarification• Column and membrane chromatography (affinity, ion exchange, size exclusion, mixed-
mode)• Bioprocess filtration (tangential flow, hollow fiber, depth filtration)• Formulation study• Viral clearance study• Long-term stability study
2021 Vigene Biosciences . All rights reserved . All trademarks are the property of Vigene Biosciences including Vigene Biosciences, Vigene, Vigene logo, Make Gene Therapy Affordable . Images are used with permission from Beckman Coulter and General Electric Company .
VigeneBiosciencesA Charles River Company
is a power combination between a leadingmanufacturer producing preclinical and CGMPPhase I/II and Phase III/commercial clinicalmaterials used in vaccine, cell & genetherapy applications for 17 years and a viralvector technology powerhouse.
■ AAV CGMP
■ Adenovirus CGMP
■ Lentivirus CGMP
■ Retrovirus CGMP
■ Plasmid GMP-Ready and CGMP
Vigene Biosciences, A Charles River Company
Ordering
[email protected] Free (USA): 1-800-485-5808
Telephone: 301-251-6638 Fax: 301-251-6110
Technical Support
Email: [email protected] Free (USA): 1-800-485-5808
Telephone: 301-251-6638 Fax: 301-251-6110